Last reviewed · How we verify
NCT04611100
Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma
NA trial testing ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) in Hilar Cholangiocarcinoma in 70 participants. Completed in 30 December 2021.
30 December 2021
Quick facts
| Lead sponsor | Department of Medical Services Ministry of Public Health of Thailand |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 April 2020 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)
Conditions studied
- Hilar Cholangiocarcinoma — all drugs for Hilar Cholangiocarcinoma →
- Biliary Obstruction — all drugs for Biliary Obstruction →
Sponsor
Department of Medical Services Ministry of Public Health of Thailand
Who can join
Adults 18 to 80, any sex, with Hilar Cholangiocarcinoma or Biliary Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aim to evaluate the efficacy of intraductal radiofrequency ablation for unresetable hilar cholangiocarcinoma in addition to biliary stenting. The patient would be randomized into 1:1 ratio of conventional group who received biliary stenting alone, and RFA group who receive intraductal RFA before biliary stenting. Immediate complications as well as long term stent patency and patient survival would be studied.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04611100
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hilar Cholangiocarcinoma
Currently open trials in the same condition.
- NCT06717464 — Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepa · Phase 2 · active not recruiting
- NCT07176962 — A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening · recruiting
Other Department of Medical Services Ministry of Public Health of Thailand trials
Trials by the same sponsor.
- NCT06665737 — Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients · Phase 4 · not yet recruiting
- NCT06763575 — Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy · NA · recruiting
- NCT06860659 — Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient With Moderate to Severe Dry Eye · Phase 4 · enrolling by invitation
- NCT06525870 — Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Control · Phase 2 · enrolling by invitation
- NCT06436833 — Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Gl · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611100 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Department of Medical Services Ministry of Public Health of Thailand
- Last refreshed: 23 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611100.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing